October 1, 2024

Supplementary Figure S1 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics

RSR. Taylor SundbyNational Institutes of Health JSJeffrey J. SzymanskiMayo Clinic APAlexander PanRedox Power Systems (United States)

Key Points

Key points are not available for this paper at this time.

Abstract

Supplemental Figure 1. Attributes of atypical neurofibroma samples. Histologic characteristics and, when available, TSO500 clinical sequencing results for paired tissue corresponding with AN cell-free DNA.

AIに質問

Bookmark

View Full Paper

Cite This Study

Sundby et al. (Tue,) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efef0c https://doi.org/https://doi.org/10.1158/1078-0432.27142189

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics2024
2Data from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics2024
3Supplementary Figure S4 from Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics2024
4Supplementary Figure S11 from Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression2024
5Supplementary Figure S11 from Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression2024

AIに質問

Bookmark

View Full Paper